Roquette to Showcase Advanced Drug Delivery and Pharmaceutical Solutions at CPHI & PMEC China 2026
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, has announced its participation in CPHI & PMEC China 2026, where the company will present a broad portfolio of innovative drug delivery technologies and pharmaceutical solutions designed to support the evolving needs of the healthcare industry. The event will take place from June 16 to June 18 at the Shanghai New International Expo Centre (SNIEC), bringing together pharmaceutical manufacturers, formulation scientists, technology providers, and industry leaders from across the globe.
Under the theme “One Roquette for Innovations,” the company’s Health & Pharma Solutions Business Unit will welcome visitors at booth E3D26, showcasing a comprehensive range of excipients, formulation technologies, biopharmaceutical solutions, and capsule delivery systems. The exhibition will highlight how Roquette combines scientific expertise, technical innovation, and manufacturing capabilities to help pharmaceutical companies transform promising drug candidates into scalable and commercially successful therapies.
As pharmaceutical development becomes increasingly complex, particularly with the rise of biologics, advanced therapies, and next-generation treatments such as GLP-1 medicines, manufacturers are seeking partners capable of supporting both innovation and reliable large-scale production. Roquette aims to demonstrate how its integrated portfolio can help address these challenges while accelerating product development and commercialization.
Supporting the Future of Pharmaceutical Innovation
The pharmaceutical industry is undergoing rapid transformation. Advances in biotechnology, precision medicine, and novel therapeutic modalities are creating new opportunities for patient care while simultaneously increasing the complexity of drug formulation and manufacturing.
Companies developing modern therapies must ensure not only the effectiveness of their products but also their stability, manufacturability, and scalability. These requirements have elevated the importance of excipients and drug delivery technologies, which play a critical role in determining product performance and commercial success.
Angela Strzelecki, Senior Vice President of the Roquette Group and Chief Executive Officer of the Health & Pharma Solutions Business Unit, emphasized the growing need for dependable partners capable of supporting innovation from early-stage development through commercial production.
According to Strzelecki, the pharmaceutical industry is facing increasing pressure to deliver robust formulations while maintaining manufacturing reliability, supply security, and quality consistency at scale. She noted that the emergence of therapies such as GLP-1 medicines and complex biologics has intensified these demands.
She explained that Roquette is uniquely positioned to address these challenges through its integrated portfolio of excipients, formulation technologies, biopharmaceutical solutions, and hard capsule systems. Supported by a broad manufacturing network and global quality standards, the company aims to serve as a trusted partner for pharmaceutical innovation throughout China and the wider Asia-Pacific region.
Spotlight on PEARLITOL® Mannitol
One of the featured products at Roquette’s exhibition booth will be PEARLITOL® mannitol, a versatile pharmaceutical excipient that has become widely recognized for its ability to support modern drug development and manufacturing requirements.
Mannitol is commonly used in pharmaceutical formulations due to its excellent stability, compatibility, and processing characteristics. Roquette’s PEARLITOL® product line has been specifically engineered to simplify formulation development while delivering reliable performance across multiple dosage forms.
The company will highlight how PEARLITOL® mannitol supports both high-dose and low-dose formulations, making it suitable for a broad range of pharmaceutical products.
Manufactured in China, the excipient also offers regional supply advantages, helping pharmaceutical companies secure dependable access to critical formulation components while reducing supply chain complexity.
In addition to supporting manufacturing efficiency, PEARLITOL® mannitol provides enhanced stability under sensitive conditions, a feature that is particularly important for modern therapeutic products that require precise formulation control.
The excipient’s consistent processability and batch-to-batch uniformity help manufacturers achieve reliable production outcomes, reducing variability and supporting regulatory compliance.
Its versatility extends across numerous applications, including oral solid dosage forms, injectable products, inhalation therapies, and biologic formulations. This flexibility makes PEARLITOL® an attractive option for companies developing diverse therapeutic portfolios.
Comprehensive Portfolio of Pharmaceutical Excipients
Beyond PEARLITOL® mannitol, Roquette plans to showcase an extensive range of pharmaceutical excipients that support formulation development across multiple therapeutic categories and delivery systems.
Among the featured products will be Avicel® microcrystalline cellulose, a widely used excipient known for its functionality in tablet manufacturing and formulation stability.
The company will also present Ac-Di-Sol® croscarmellose sodium, a superdisintegrant commonly used to enhance tablet disintegration and drug release performance.
Other important products on display include METHOCEL™ hydroxypropyl methylcellulose (HPMC), ETHOCEL™ ethylcellulose, and POLYOX™ polyethylene oxide, each offering specialized functionality for controlled release formulations, extended-release applications, and advanced drug delivery systems.
Together, these excipients provide pharmaceutical manufacturers with a toolkit for addressing formulation challenges while optimizing product performance and manufacturability.
Advanced Formulation Technologies
As pharmaceutical products become increasingly sophisticated, formulation technologies have become essential for improving bioavailability, stability, patient adherence, and therapeutic effectiveness.
Roquette will demonstrate how its formulation expertise supports a wide variety of dosage forms and delivery strategies.
The company’s portfolio includes solutions for oral solid dosage forms, one of the most widely used methods of drug administration worldwide. These technologies help manufacturers develop tablets and capsules with improved performance characteristics and production efficiency.
Visitors will also learn about Roquette’s controlled-release technologies, which enable drugs to be released gradually over time, helping maintain therapeutic levels and potentially improving patient compliance.
In addition, the company will highlight specialty formulation capabilities designed to address complex drug development challenges, including those associated with difficult-to-formulate active pharmaceutical ingredients.
These advanced technologies illustrate Roquette’s commitment to helping pharmaceutical companies navigate increasingly demanding formulation requirements.
Growing Capabilities in Biopharmaceutical Solutions
Biopharmaceuticals continue to represent one of the fastest-growing segments of the pharmaceutical industry, creating demand for innovative technologies that support the development and manufacturing of complex biological therapies.
At CPHI China 2026, Roquette will showcase several solutions specifically designed for biopharmaceutical applications.
Among these is KLEPTOSE® beta-cyclodextrin technology, which can help stabilize proteins and other sensitive molecules. Protein stabilization remains a critical challenge in biologics development, and advanced excipients play an important role in preserving therapeutic integrity throughout manufacturing and storage.
Roquette will also feature NOVAMATRIX-3D™ alginate foams, which support three-dimensional cell culture applications.
Three-dimensional cell culture systems are becoming increasingly important in biomedical research, drug discovery, regenerative medicine, and advanced therapy development because they more accurately mimic biological environments compared to traditional cell culture methods.
These offerings demonstrate Roquette’s expanding role in supporting innovation across both traditional pharmaceuticals and emerging biopharmaceutical technologies.
Hard Capsules and Integrated Drug Delivery Systems
Another major area of focus at the exhibition will be Qualicaps by Roquette, the company’s hard capsule business.
Qualicaps offers a comprehensive portfolio of capsule solutions, including both hydroxypropyl methylcellulose (HPMC) and gelatin capsules.
These capsules support a variety of oral and inhalation drug delivery applications and are widely used by pharmaceutical manufacturers around the world.
As patient preferences and formulation requirements continue to evolve, demand for high-quality capsule technologies remains strong. Roquette’s integrated capsule offerings are designed to meet these changing needs while maintaining consistent quality and performance.
The company’s capsule expertise complements its broader excipient and formulation portfolio, enabling customers to access multiple drug delivery solutions through a single partner.
End-to-End Support Across the Drug Development Journey
A key message Roquette plans to emphasize during CPHI China 2026 is its ability to provide end-to-end support throughout the pharmaceutical development lifecycle.
From initial formulation research and excipient selection to process optimization and commercial-scale manufacturing, the company offers technical expertise aimed at helping customers overcome development challenges and accelerate time to market.
This integrated approach is increasingly valuable as pharmaceutical companies seek to streamline development processes and reduce the risks associated with scaling innovative therapies.
By combining scientific knowledge, manufacturing capabilities, and global technical support, Roquette aims to serve as a strategic partner rather than simply a supplier of pharmaceutical ingredients.
As one of the pharmaceutical industry’s most important events in Asia, CPHI & PMEC China 2026 provides an ideal platform for showcasing the technologies shaping the future of drug development and manufacturing.
Roquette’s participation reflects its commitment to supporting pharmaceutical innovation through advanced excipients, formulation technologies, biopharmaceutical solutions, and integrated drug delivery systems.
Visitors to booth E3D26 will have the opportunity to engage directly with the company’s scientific and technical experts, explore the latest advances in pharmaceutical formulation, and learn how Roquette’s solutions can help address the growing challenges associated with formulation complexity, manufacturing scalability, and commercial production.
With increasing demand for innovative therapies across China and the broader Asia-Pacific region, Roquette continues to position itself as a trusted partner helping pharmaceutical companies transform scientific breakthroughs into successful and accessible medicines for patients worldwide.
About Roquette
Roquette is a global leader in sustainable plant-based solutions, driving innovation and strong partnerships that are shaping the future of nutrition, health, and bioindustry.
The company harnesses natural resources such as wheat, corn, seaweed, and cellulose to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products.
A family-owned company with over 90 years of expertise and 11,000 employees, Roquette serves clients in over 150 countries and is committed to creating lasting value for customers, patients, consumers, and society.
Together, we turn the potential of nature into the essentials of life.
